In March 20th, according to the official WeChat official account of China Meheco Group Co.Ltd(600056) , in March 19th, China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) and the first COVID-19 virus treatment drug PAXLOVID, which were co operated with Pfizer, had been transported to the Daxing logistics center of China Meheco Group Co.Ltd(600056) . All goods were closed to the whole process according to the import and export related epidemic prevention requirements, and the relevant work such as acceptance and warehousing had been completed.
China Meheco Group Co.Ltd(600056) said that at present, the company has received the order of urgent drug guarantee, and all drugs are being transported to the front line of national anti epidemic
China Meheco Group Co.Ltd(600056) WeChat public official account for more than 5 o’clock in the morning of March 20th. The special transport vehicle loaded with COVID-19 virus treatment drug Paxlovid starts from China Meheco Group Co.Ltd(600056) Daxing logistics center and sailed to Changchun City, Jilin Province, which marks the opening of the drug insurance action for China Meheco Group Co.Ltd(600056) COVID-19 treatment support for the epidemic. the batch of drugs is expected to arrive in Changchun, Jilin Province today. After arrival, the drugs will be sent to the front line of anti epidemic immediately
On March 9, China Meheco Group Co.Ltd(600056) announced that signed a supply agreement with Pfizer on March 9, 2022. The company will be responsible for the commercial operation of Pfizer Inc COVID-19 virus PAXLOVID in Chinese mainland market during the agreement period (2022).
paxlovid is an oral small molecule covid-19 virus treatment drug, which is a treatment method combined with naimatvir and ritonavir in February 11th this year, the State Food and Drug Administration (nsfda), in accordance with the relevant provisions of the drug administration law, carried out emergency review and approval in accordance with the special examination and approval procedures of drugs. It approved the registration of Pfizer Inc’s COVID-19 virus treatment drug nemertave tablets / Ritonavir Tablets combined package (Paxlovid) with the conditional approval to treat patients with mild to moderate New Coronavirus pneumonia (COVID-19) accompanied by severe risk factors in adults, such as those with advanced age. Patients with severe risk factors such as chronic kidney disease, diabetes, cardiovascular disease and chronic lung disease.
In March 15th, the national health and Health Committee released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). The main points of revision showed that the specific anti Paxlovid COVID-19 drugs approved by the State Administration of drug administration were written into the treatment plan.
On March 18, China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) announced the change, saying that on March 17, the company completed the import customs clearance procedures of the first batch of this product and is fully cooperating with the state in the fight against covid-19 epidemic the final use and sales of the product are affected by epidemic prevention and control and other factors, there is great uncertainty, and it is estimated that the scale of relevant business accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
Recently, China Meheco Group Co.Ltd(600056) share price has risen sharply. From March 2, 2022 to March 18, 2022, 13 trading days have been subject to 10 price limits, with a cumulative increase of nearly 200%, and has touched the abnormal fluctuation of stock trading for the fifth time
As of the closing on March 18, China Meheco Group Co.Ltd(600056) rose again to close at 33.26 yuan, with a market value of 35.54 billion yuan.
